•Benchmark of 6 SA codes (14 participants) for two accident scenarios in a Spent Fuel Pool.•Differences in draining velocity induced scattering in the onset of fuel heat-up (LOCA scenario).•For both ...scenarios, important spreading in the heating rate and hydrogen production.•Discrepancies due to differences in physical models and in the representation of the storage racks.•Criticality risk assessment by 5 participants with a rather good agreement of the results.
Spent fuel pools (SFPs) are large structures equipped with storage racks designed to temporarily store irradiated nuclear fuel removed from the reactor. SFP severe accidents have long been considered as highly improbable since the accident progression is slow (in comparison with reactor core accidents) and let time to corrective operator actions. However, the accident at the Fukushima Dai-ichi Nuclear Power Plants has highlighted the vulnerability of nuclear fuels that are stored in SFPs in case of prolonged loss-of-cooling accidents and consequently renewed international interest in the safety of SFPs. In this context, the AIR-SFP project, funded by the Euratom 7th FP in the frame of the NUGENIA+ project, was launched in May 2015 with 15 participants. One of the objectives was to assess the applicability of Severe Accident (SA) codes, which were initially developed for reactor applications, to the calculation of transients in SFPs. To reach this objective, a benchmark, including a criticality risk assessment, was carried out. The degradation progression was computed by 14 participants with 6 different SA codes and 5 have participated to the criticality risk assessment. Main results are presented as well as conclusions that have been drawn concerning SA codes readiness to address these “beyond-scope” scenarios.
We evaluated a novel therapy for primary central nervous system lymphoma (PCNSL) with induction immunochemotherapy with high-dose methotrexate, temozolomide, and rituximab (MT-R) followed by ...intensive consolidation with infusional etoposide and high-dose cytarabine (EA). In addition, we evaluated the prognostic value of the minimum apparent diffusion coefficient (ADC(min)) derived from diffusion-weighted MRI (DW-MRI) in patients treated with this regimen.
Thirty-one patients (median age, 61 years; median Karnofsky performance score, 60) received induction with methotrexate every 14 days for 8 planned cycles. Rituximab was administered the first 6 cycles and temozolomide administered on odd-numbered cycles. Patients with responsive or stable central nervous system (CNS) disease received EA consolidation. Pretreatment DW-MRI was used to calculate the ADC(min) of contrast-enhancing lesions.
The complete response rate for MT-R induction was 52%. At a median follow-up of 79 months, the 2-year progression-free and overall survival were 45% and 58%, respectively. For patients receiving EA consolidation, the 2-year progression-free and overall survival were 78% and 93%, respectively. EA consolidation was also effective in an additional 3 patients who presented with synchronous CNS and systemic lymphoma. Tumor ADC(min) less than 384 × 10(-6) mm(2)/s was significantly associated with shorter progression-free and overall survival.
MT-R induction was effective and well tolerated. MT-R followed by EA consolidation yielded progression-free and overall survival outcomes comparable to regimens with chemotherapy followed by whole-brain radiotherapy consolidation but without evidence of neurotoxicity. Tumor ADC(min) derived from DW-MRI provided better prognostic information for PCNSL patients treated with the MTR-EA regimen than established clinical risk scores.
Background.This study investigates whether dose modifications for adverse hematologic effects or the use of hematopoietic growth factors influenced the outcome of therapy for hepatitis C virus (HCV) ...infection in patients who were coinfected with HCV and human immunodeficiency virus (HIV) and who were participants in a randomized, controlled trial. Methods.Subjects were randomized to receive ribavirin plus interferon-alfa-2a (IFN-alfa-2a) or pegylated IFN-alfa-2a for a total of 48 weeks. Doses were modified for a number of adverse effects (including hematologic toxicity), and hematopoietic growth factors were administered at the discretion of the physician. Associations of dose modifications or initiation of hematopoietic growth factor support with treatment outcomes were determined by standard statistical methods. Results.One hundred thirty-three subjects were included in this study. Subjects treated with pegylated IFN-alfa-2a were more likely to have had dose modifications (dose reduction or discontinuation) than were those treated with IFN-alfa-2a. By multivariate analysis, treatment with pegylated IFN-alfa-2a is associated with higher sustained virologic and/or histologic response. Dose modifications for nonhematologic toxicity are independently associated with lower sustained virologic and/or histologic responses. Although hematologic toxicity was not directly associated with clinical outcome in this analysis, use of hematopoietic growth factors was associated with an increased sustained virologic and/or histologic response. Conclusions.Dose modifications for anti-HCV therapy may adversely affect the outcome of treatment of HCV in individuals who are coinfected with HIV. The use of hematopoietic growth factor support may be associated with an improved clinical response to therapy.
Do people self-enhance by dwelling in righteous anger in an effort to preserve their self-views as pillars of morality? We addressed this question in two experiments. Participants read a story about ...an injustice (experiencing righteous anger) or grocery shopping (experiencing neutral emotion), indicated their interest in reading injustice-relevant or happiness-relevant newspaper articles, and rated themselves on moral and agentic traits. Participants who experienced righteous anger (vs. neutral emotion) maintained their anger (i.e., exhibited stronger interest in reading injustice- than happiness-relevant articles) and rated themselves more positively on moral, but not on agentic, traits. Furthermore, anger maintenance mediated the effect of righteous anger on moral grandiosity. The findings illustrate tactical self-enhancement: the instrumental use of one's negative emotions for self-enhancement purposes.
Patients undergoing antiviral therapy for chronic hepatitis C often develop anemia secondary to ribavirin and interferon. Recombinant erythropoietin has been used to improve anemia associated with ...antiviral therapy and to minimize dose reductions, which are associated with decreased rates of sustained virologic response. A rare potential side effect of recombinant erythropoietin is anti-erythropoietin antibody associated pure red cell aplasia. In chronic kidney disease patients with this entity, there have been good outcomes associated with renal transplant and subsequent immunosuppression. In this case, a chronic liver disease patient developed anti-erythropoietin associated pure red cell aplasia and recovered after liver transplantation and immunosuppression. It is unclear whether it is the transplanted organ, the subsequent immunosuppression, or the combination that contributed to the response. In conclusion, anti-erythropoietin associated pure red cell aplasia is a serious complication of erythropoietin therapy, but this entity should not be considered a contraindication for solid organ transplantation.
The KS→π+π−e+e− decay mode was investigated using the data collected in 2002 by the NA48/1 Collaboration. With about 23 k KS→π+π−e+e− events and 59 k KL→π+π−πD0 normalization decays, the KS→π+π−e+e− ...branching ratio relative to the KL→π+π−πD0 one was determined to be BR(KS→π+π−e+e−)/BR(KL→π+π−πD0)=(3.28±0.06stat±0.04syst)×10−2. This result was used to set the upper limit |gE1/gBR|<3.0 at 90% CL on the presence, in the decay amplitude, of an E1 direct emission (gE1) term relative to the dominant inner bremsstrahlung (gBR) term. The CP-violating asymmetry Aϕ in the sinϕcosϕ distribution of KS→π+π−e+e− events, where ϕ is the angle between the π+π− and the e+e− decay planes in the kaon centre of mass, was found to be Aϕ=(−0.4±0.8)%, consistent with zero. These results are in good agreement with a description of the KS→π+π−e+e− decay amplitude dominated by the CP-even inner bremsstrahlung process.
The NA48/2 experiment at CERN collected a large sample of charged kaon decays to final states with multiple charged particles in 2003–2004. A new upper limit on the rate of the lepton number ...violating decay K±→π∓μ±μ± is reported: B(K±→π∓μ±μ±)<8.6×10−11 at 90% CL. Searches for two-body resonances X in K±→πμμ decays (such as heavy neutral leptons N4 and inflatons χ) are also presented. In the absence of signals, upper limits are set on the products of branching fractions B(K±→μ±N4)B(N4→πμ) and B(K±→π±X)B(X→μ+μ−) for ranges of assumed resonance masses and lifetimes. The limits are in the (10−11,10−9) range for resonance lifetimes below 100 ps.
INTRODUCTIONPure red cell aplasia due to anti-epoetin antibodies is a known complication of epoetin therapy for anemia due to chronic kidney disease. This disease has not previously been well ...described in the setting of therapy for chronic hepatitis C virus infection. While treatment for pure red cell aplasia due to anti-epoetin antibodies is usually with immunosuppressive therapy such as calcineurin inhibition, the safety of this treatment in chronic hepatitis C virus infection is unknown. To date, little has been published on the efficacy of rituximab on pure red cell aplasia due to anti-epoetin antibodies. CASE PRESENTATIONThis report describes a 65-year-old Asian-American woman who developed pure red cell aplasia from high titer neutralizing anti-epoetin antibodies after epoetin-alfa therapy during ribavirin and peg-interferon treatment for chronic hepatitis C virus infection. We describe the outcome of her treatment with rituximab. The reticulocyte count increased, and anti-epoetin antibody titer decreased with a loss of neutralizing activity in vitro, leading to a reduction in blood transfusions, and eventual resolution of anemia, without reactivation of hepatitis C virus. CONCLUSIONThe diagnosis of pure red cell aplasia from anti-epoetin antibodies should be considered in patients undergoing therapy for chronic hepatitis C virus infection who develop severe anemia after administration of erythropoietin or darbepoetin. Though it is currently an off-label indication, rituximab is a therapeutic option for patients with pure red cell aplasia due to anti-epoetin antibodies.
PDF
